E2 ModerateModerate confidencePEM not requiredCross-SectionalPeer-reviewedReviewed
Standard · 3 min
Metabolic analysis of amino acids and vitamin B6 pathways in lymphoma survivors with cancer related chronic fatigue.
Fosså, Alexander, Smeland, Knut Halvor, Fluge, Øystein et al. · PloS one · 2020 · DOI
Quick Summary
This study looked at blood chemicals called amino acids and B vitamins in lymphoma survivors who experienced lasting fatigue after cancer treatment. Researchers found that people with this fatigue had lower tryptophan (an amino acid) and signs of ongoing low-level immune activation and inflammation. The study suggests that persistent tiredness after lymphoma treatment may be caused by the body's immune system staying activated longer than expected.
Why It Matters
This study identifies potential biological mechanisms underlying post-cancer fatigue through metabolite analysis, offering insights into immune activation and tryptophan metabolism that may be relevant to ME/CFS pathophysiology. Finding metabolic and immune markers associated with chronic fatigue in cancer survivors strengthens the case that chronic fatigue syndromes have measurable biological underpinnings, supporting the need for biomarker-driven diagnostic and therapeutic approaches.
Observed Findings
Tryptophan levels were significantly reduced in both male and female lymphoma survivors with cancer-related fatigue compared to non-fatigued survivors.
Kynurenine/tryptophan ratio was elevated in fatigued survivors, indicating increased tryptophan degradation via the kynurenine pathway.
Vitamin B6 catabolism marker (PAr index) was elevated in fatigued survivors and correlated with immune activation markers (neopterin, CRP, IL-6).
Higher neuroticism score, obesity, and elevated PAr index were independently associated with increased risk of chronic fatigue.
Inferred Conclusions
Low-grade immune activation and chronic inflammation contribute to cancer-related fatigue in lymphoma survivors post-stem cell transplantation.
Tryptophan metabolism dysregulation and accelerated B6 catabolism are associated with persistent fatigue in this population.
Metabolic and psychological factors (neuroticism, obesity) may interact with immunological dysfunction to increase fatigue risk.
Remaining Questions
Does the tryptophan deficit directly cause fatigue, or is it a consequence of prolonged immune activation after transplantation?
Would interventions targeting tryptophan repletion, B6 supplementation, or immune modulation reduce fatigue symptoms in this population?
What This Study Does Not Prove
This study does not prove that low tryptophan or elevated B6 catabolism *cause* chronic fatigue—only that they correlate with it. The cross-sectional design cannot establish temporal relationships or rule out that fatigue itself drives these metabolic changes. Results are specific to lymphoma survivors after stem cell transplantation and may not generalize to other cancer types or ME/CFS populations without independent validation.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
How do these metabolic and immune findings in post-transplant lymphoma survivors compare mechanistically to ME/CFS and other chronic fatigue disorders?
Do these biomarkers predict fatigue onset or persistence, and could they be used for early intervention or treatment monitoring?